BridgeBio Pharma Files 8-K on Shareholder Votes and Exhibits
Ticker: BBIO · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financials, filing
TL;DR
BridgeBio filed an 8-K on 6/24 for shareholder votes & financials from 6/21.
AI Summary
BridgeBio Pharma, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The earliest event reported was on June 21, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations industry.
Why It Matters
This filing indicates important corporate actions and financial disclosures that investors and stakeholders should review for company updates.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and financial disclosures, not indicating immediate operational or financial distress.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- June 24, 2024 (date) — Date of Report
- June 21, 2024 (date) — Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
- 3160 Porter Dr., Suite 250, Palo Alto, CA 94304 (address) — Principal Executive Offices
- (650) 391-9740 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of the vote are not provided in this excerpt.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in this excerpt.
When was BridgeBio Pharma, Inc. incorporated?
BridgeBio Pharma, Inc. was incorporated in Delaware.
What is BridgeBio Pharma's primary business classification?
BridgeBio Pharma's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where are BridgeBio Pharma's principal executive offices located?
BridgeBio Pharma's principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-06-24 16:01:15
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
Filing Documents
- ef20031581_8k.htm (8-K) — 58KB
- ef20031581_ex10-1.htm (EX-10.1) — 104KB
- 0001140361-24-031087.txt ( ) — 322KB
- bbio-20240621.xsd (EX-101.SCH) — 4KB
- bbio-20240621_lab.xml (EX-101.LAB) — 21KB
- bbio-20240621_pre.xml (EX-101.PRE) — 16KB
- ef20031581_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. The proposals set forth below were submitted to the stockholders at the Annual Meeting of Stockholders (the "Annual Meeting") of BridgeBio Pharma, Inc. (the "Company") held on June 21, 2024, with each such proposal described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 25, 2024. The number of shares of common stock entitled to vote at the Annual Meeting was 187,129,260. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 160,899,203. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below. Proposal 1 - Election of Directors. The Company's stockholders elected the five (5) director nominees below to the Company's Board of Directors as Class II directors to hold office until the 2027 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Eric Aguiar, M.D. 139,080,658 4,552,096 Jennifer E. Cook 139,063,404 4,569,350 Andrea J. Ellis 139,229,888 4,402,866 Fred Hassan 137,076,192 6,556,562 Ali J. Satvat 106,237,448 37,395,306 There were 17,266,449 broker non-votes regarding this proposal. Proposal 2 - Non-binding Advisory Vote on Compensation of Named Executive Officers. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. Votes For Votes Against Abstentions 134,309,832 9,254,636 68,286 There were 17,266,449 broker non-votes regarding this proposal. Proposal 3 - Ratification of Appointment of Independent Registered Accounting Firm. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fis
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIDGEBIO PHARMA, INC. Date: June 24, 2024 By: /s/ Brian C. Stephenson Name: Brian C. Stephenson Title: Chief Financial Officer